Case Report
Multi Insulin Sensitization with Tolerante to New Therapeutic Option: Degludec
Author(s): Debora Nakatani Lopes, Wilson Carlos Tartuce Aun, Joao Ferreira de Mello and Adriana Teixeira RodriguesDebora Nakatani Lopes, Wilson Carlos Tartuce Aun, Joao Ferreira de Mello and Adriana Teixeira Rodrigues
Introduction: Insulin has been used for the treatment of diabetes mellitus (DM) since 1920. At first, the animal insulins were available for human use having frequent allergic reactions due to the differences in amino acid sequences with human insulin. Currently, with the use of human insulin, the prevalence of these reactions is around 2% and less than a third of these events were associated with insulin itself. These cases are associated with their additives or preservatives. The most commonly hypersensitivity reaction found is type I. In these cases, the use of a rapid-acting insulin is the best therapeutic alternative. We report the case of a multi-sensibilizated patient to insulin presenting tolerance to the ultralong-acting: Degludec insulin. Case report: Female patient, 74, referring use of NPH (Neutral Protamine Hagedorn) human insulin for 5 y.. View More»
